Aptevo Therapeutics (APVO) Income towards Parent Company (2015 - 2026)

Aptevo Therapeutics has reported Income towards Parent Company for 11 years, with the latest figure at -$7.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 5.23% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.2 million (down 328.18% YoY) and the FY2025 annual result came in at -$32.3 million, changed N/A from the prior year.
• Income towards Parent Company declined to -$7.2 million in Q1 2026 per APVO's latest filing, from -$6.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $946000.0 in Q1 2023 and troughed at -$8.6 million in Q3 2025.
• A 4-year average of -$3.1 million and a median of $149000.0 in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company tumbled 57.0% in 2022, then surged 431.46% in 2023.
• Over 4 years, Income towards Parent Company stood at $521000.0 in 2022, then slumped by 43.76% to $293000.0 in 2023, then sank by 2312.29% to -$6.5 million in 2025, then decreased by 10.78% to -$7.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$7.2 million, -$6.5 million, and -$8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.